SenzaGen AB reported a 13% year-over-year increase in second-quarter revenue to SEK 15.3 million, supported by a rebound at its VitroScreen subsidiary. The Swedish non-animal testing company attributed the growth to higher order intake at VitroScreen, which rose both sequentially and versus the prior-year period and included two major contracts secured during the quarter.
The company narrowed its operating loss in Q2 while improving earnings per share compared with the same period last year. Gross margins remained stable relative to historical levels, and SenzaGen generated positive operating cash flow, citing disciplined cost management as a key factor.
For the first half of the year, total revenue reached SEK 30.20 million, with a loss per share of SEK 0.13. Management highlighted long-term tailwinds from the European Union’s phased approach to phasing out animal testing, which it expects to reinforce demand for non-animal testing solutions. The firm also pointed to ongoing strategic initiatives and regulatory trends as supportive of its trajectory toward sustainable profitability.
